Supreme Court Ruling Raises Biosimilars’ Access

Monday June 19, 2017

PBMs and health-care groups praised the recent U.S. Supreme Court decision that is expected to accelerate patients’ access to biosimilar medications.

The ruling in the case, Sandoz Inc. v. Amgen Inc., allows biosimilar manufacturers to give marketing notice before FDA approval so that their products can get to market quicker.

“The Supreme Court’s decision today is a huge victory for American patients and consumers,” said Chip Davis, President and CEO of the Association for Accessible Medicines (AAM). “This ruling will help provide faster access to lower-cost biosimilar medicines for millions of patients facing diseases such as several forms of cancer, rheumatoid arthritis, psoriasis, multiple sclerosis, and other life-threatening conditions.”

 “This ruling should help expand access and lower prescription drug costs for employers, health plans, labor unions, and Medicare,” said PBM Express Scripts in a statement provided to Drug Topics. “At a time when the cost of complex biologic specialty drugs is growing at double-digit rates, payers need every tool in their arsenal to bring cost-effective solutions to market. Express Scripts continues to champion for a clear pathway to expand the appropriate use of biosimilars.”

Read the full article on Modern Medicine Network

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.

  • This field is for validation purposes and should be left unchanged.

Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:

February 14-16, 2022 | Orlando, Florida

Access! brings together policymakers, influential speakers and industry leaders to chart the future of generics and biosimilars. This year, we're pleased to be meeting in person for the first time since 2019! Sign up before December 31, 2021 to receive $500 off your full-pass registration.

Recent Tweets

Proposals included in #BuildBackBetter undermine the progress and promise of future #biosimilar savings, particularly for employers and patients in commercial health insurance markets.

Learn more in our latest blog post:

Load More...